Suppr超能文献

2001 - 2010年美国常染色体显性多囊肾病导致的终末期肾病

ESRD from autosomal dominant polycystic kidney disease in the United States, 2001-2010.

作者信息

Reule Scott, Sexton Donal J, Solid Craig A, Chen Shu-Cheng, Collins Allan J, Foley Robert N

机构信息

Department of Medicine, University of Minnesota, Minneapolis, MN; United States Renal Data System, Minneapolis Medical Research Foundation, Minneapolis, MN.

United States Renal Data System, Minneapolis Medical Research Foundation, Minneapolis, MN.

出版信息

Am J Kidney Dis. 2014 Oct;64(4):592-9. doi: 10.1053/j.ajkd.2014.05.020. Epub 2014 Aug 16.

Abstract

BACKGROUND

Autosomal dominant polycystic kidney disease (ADPKD) is amenable to early detection and specialty care. Thus, while important to patients with the condition, end-stage renal disease (ESRD) from ADPKD also may be an indicator of the overall state of nephrology care.

STUDY DESIGN

Retrospective cohort study of temporal trends in ESRD from ADPKD and pre-renal replacement therapy (RRT) nephrologist care, 2001-2010 (n = 23,772).

SETTING & PARTICIPANTS: US patients who initiated maintenance RRT from 2001 through 2010 (n = 1,069,343) from US Renal Data System data.

PREDICTOR

ESRD from ADPKD versus from other causes for baseline characteristics and clinical outcomes; interval 2001-2005 versus 2006-2010 for comparisons of cohort of patients with ESRD from ADPKD.

OUTCOMES

Death, wait-listing for kidney transplant, kidney transplantation.

MEASUREMENTS

US census data were used as population denominators. Poisson distribution was used to compute incidence rates (IRs). Incidence ratios were standardized to rates in 2001-2002 for age, sex, and race/ethnicity. Patients with and without ADPKD were matched to compare clinical outcomes. Poisson regression was used to calculate IRs and adjusted HRs for clinical events after inception of RRT.

RESULTS

General population incidence ratios in 2009-2010 were unchanged from 2001-2002 (incidence ratio, 1.02). Of patients with ADPKD, 48.1% received more than 12 months of nephrology care before RRT; preemptive transplantation was the initial RRT in 14.3% and fistula was the initial hemodialysis access in 35.8%. During 4.9 years of follow-up, patients with ADPKD were more likely to be listed for transplantation (IR, 11.7 [95% CI, 11.5-12.0] vs 8.4 [95% CI, 8.2-8.7] per 100 person-years) and to undergo transplantation (IR, 9.8 [95% CI, 9.5-10.0] vs 4.8 [95% CI, 4.7-5.0] per 100 person-years) and less likely to die (IR, 5.6 [95% CI, 5.4-5.7] vs 15.5 [95% CI, 15.3-15.8] per 100 person-years) than matched controls without ADPKD.

LIMITATIONS

Retrospective nonexperimental registry-based study of associations; cause-and-effect relationships cannot be determined.

CONCLUSIONS

Although outcomes on dialysis therapy are better for patients with ADPKD than for those without ADPKD, access to predialysis nephrology care and nondeclining ESRD rates may be a cause for concern.

摘要

背景

常染色体显性遗传性多囊肾病(ADPKD)适合早期检测和专科护理。因此,虽然对患有该疾病的患者很重要,但ADPKD导致的终末期肾病(ESRD)也可能是肾脏病护理总体状况的一个指标。

研究设计

对2001 - 2010年期间ADPKD导致的ESRD及肾替代治疗(RRT)前肾脏病专家护理的时间趋势进行回顾性队列研究(n = 23,772)。

设置与参与者

根据美国肾脏数据系统数据,2001年至2010年开始维持性RRT的美国患者(n = 1,069,343)。

预测因素

ADPKD导致的ESRD与其他原因导致的ESRD的基线特征和临床结局;2001 - 2005年与2006 - 2010年对ADPKD导致的ESRD患者队列进行比较。

结局

死亡、等待肾移植、肾移植。

测量方法

美国人口普查数据用作人群分母。采用泊松分布计算发病率(IR)。发病率比按2001 - 2002年的年龄、性别和种族/民族率进行标准化。对有和没有ADPKD的患者进行匹配以比较临床结局。采用泊松回归计算RRT开始后临床事件的IR和调整后的HR。

结果

2009 - 2010年的总体人群发病率比与2001 - 2002年相比无变化(发病率比,1.02)。在患有ADPKD的患者中,48.1%在RRT前接受了超过12个月的肾脏病护理;抢先移植是14.3%患者的初始RRT,而内瘘是35.8%患者的初始血液透析通路。在4.9年的随访期间,与匹配的无ADPKD对照组相比,患有ADPKD的患者更有可能被列入移植名单(IR,每100人年11.7 [95% CI,11.5 - 12.0]对8.4 [95% CI,8.2 - 8.7]),更有可能接受移植(IR,每100人年9.8 [95% CI,9.5 - 10.0]对4.8 [95% CI,4.7 - 5.0]),且死亡可能性更小(IR,每100人年5.6 [95% CI,5.4 - 5.7]对15.5 [95% CI,15.3 - 15.8])。

局限性

基于回顾性非实验性登记研究的关联;无法确定因果关系。

结论

虽然ADPKD患者的透析治疗结局优于无ADPKD患者,但透析前肾脏病护理的可及性和ESRD发病率无下降可能令人担忧。

相似文献

1
ESRD from autosomal dominant polycystic kidney disease in the United States, 2001-2010.
Am J Kidney Dis. 2014 Oct;64(4):592-9. doi: 10.1053/j.ajkd.2014.05.020. Epub 2014 Aug 16.
2
Health Disparities in Autosomal Dominant Polycystic Kidney Disease (ADPKD) in the United States.
Clin J Am Soc Nephrol. 2022 Jul;17(7):976-985. doi: 10.2215/CJN.00840122. Epub 2022 Jun 20.
4
Epidemiology of patients in England and Wales with autosomal dominant polycystic kidney disease and end-stage renal failure.
Nephrol Dial Transplant. 2014 Oct;29(10):1910-8. doi: 10.1093/ndt/gfu087. Epub 2014 Apr 15.
5
[REIN Report 2011--summary].
Nephrol Ther. 2013 Sep;9 Suppl 1:S3-6. doi: 10.1016/S1769-7255(13)70036-1.
7
Mortality risk in patients with autosomal dominant polycystic kidney disease.
BMC Nephrol. 2024 Feb 16;25(1):56. doi: 10.1186/s12882-024-03484-3.
8
International comparison of trends in patients commencing renal replacement therapy by primary renal disease.
Nephrology (Carlton). 2019 Oct;24(10):1064-1076. doi: 10.1111/nep.13531. Epub 2019 Apr 29.
9
Revisiting racial differences in ESRD due to ADPKD in the United States.
BMC Nephrol. 2019 Feb 14;20(1):55. doi: 10.1186/s12882-019-1241-1.
10
Is CAPD a viable option among ADPKD with end stage renal disease population in India? Its outcomes and economics.
Saudi J Kidney Dis Transpl. 2015 Sep;26(5):906-11. doi: 10.4103/1319-2442.164570.

引用本文的文献

1
Autosomal dominant polycystic kidney disease: an overview of recent genetic and clinical advances.
Ren Fail. 2025 Dec;47(1):2492374. doi: 10.1080/0886022X.2025.2492374. Epub 2025 Apr 23.
2
Effect of Race on Transplantation in Autosomal Dominant Polycystic Kidney Disease.
Clin J Am Soc Nephrol. 2025 Apr 1;20(4):563-572. doi: 10.2215/CJN.0000000626. Epub 2025 Jan 28.
3
A miRNA-Based Approach in Autosomal Dominant Polycystic Kidney Disease: Challenges and Insights from Adult to Pediatric Evidence.
Mol Diagn Ther. 2025 Mar;29(2):183-193. doi: 10.1007/s40291-024-00761-7. Epub 2025 Jan 17.
5
Mortality risk in patients with autosomal dominant polycystic kidney disease.
BMC Nephrol. 2024 Feb 16;25(1):56. doi: 10.1186/s12882-024-03484-3.
6
Predicting autosomal dominant polycystic kidney disease progression: review of promising Serum and urine biomarkers.
Front Pediatr. 2023 Nov 10;11:1274435. doi: 10.3389/fped.2023.1274435. eCollection 2023.
7
Evaluation of advanced imaging biomarkers at kidney failure in patients with ADPKD: a pilot study.
Clin Kidney J. 2023 May 23;16(10):1691-1700. doi: 10.1093/ckj/sfad114. eCollection 2023 Oct.
8
Autosomal dominant polycystic kidney disease in Colombia.
BMC Nephrol. 2023 Jul 17;24(1):211. doi: 10.1186/s12882-023-03266-3.

本文引用的文献

1
Tolvaptan in autosomal dominant polycystic kidney disease.
N Engl J Med. 2013 Mar 28;368(13):1258-9. doi: 10.1056/NEJMc1300762.
2
US Renal Data System 2012 Annual Data Report.
Am J Kidney Dis. 2013 Jan;61(1 Suppl 1):A7, e1-476. doi: 10.1053/j.ajkd.2012.11.031.
3
Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study.
Nephrol Dial Transplant. 2012 Sep;27(9):3560-7. doi: 10.1093/ndt/gfs264. Epub 2012 Jul 10.
5
Improved prognosis in patients with autosomal dominant polycystic kidney disease in Denmark.
Clin J Am Soc Nephrol. 2010 Nov;5(11):2034-9. doi: 10.2215/CJN.01460210. Epub 2010 Jul 29.
6
Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.
J Am Soc Nephrol. 2010 Jun;21(6):1052-61. doi: 10.1681/ASN.2009121291. Epub 2010 Apr 29.
7
Trends in incidence of end-stage renal disease in Japan, 1983-2000: age-adjusted and age-specific rates by gender and cause.
Nephrol Dial Transplant. 2004 Aug;19(8):2044-52. doi: 10.1093/ndt/gfh317. Epub 2004 Jun 1.
8
Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999.
Nephrol Dial Transplant. 2003 Sep;18(9):1824-33. doi: 10.1093/ndt/gfg233.
10
Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota: 1935-1980.
Am J Kidney Dis. 1983 May;2(6):630-9. doi: 10.1016/s0272-6386(83)80044-4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验